In rodent models, it reduced body fat by up to 50% without increasing blood glucose. For the biohacker or the physique athlete, this is the holy grail: spot reduction of abdominal fat without the diabetes risk of HGH or the appetite suppression of Semaglutide.
Until the patent holders run a human trial (unlikely, as GLP-1s are more profitable), Fragment 176-191 will remain what it has always been: the most popular research chemical that nobody should actually research on themselves.
The deep market exists for the advanced user: The bodybuilder who has maxed out GLP-1s and Clenbuterol. The longevity researcher who has a mass spectrometer at home. The person for whom €500 is worth the gamble to see if a rat study translates to humans.
Dubbed the "non-diabetic fat burner" and the "tummy tuck in a vial," this synthetic polypeptide is a specific slice of the human growth hormone molecule. While pharmaceutical giants spend billions on GLP-1 agonists like Ozempic, a different, more underground economy is thriving. It is the economy of lyophilized powder shipped in unmarked vials from Chinese labs to your mailbox.
User reports (n=1,000+ scraped from forums) indicate a 2-4% reduction in body fat over 8 weeks—comparable to a moderate diet. The "stubborn belly fat" claim holds up anecdotally, but no more than a calorie deficit.
Due to its half-life of ~30 minutes, Fragment must be injected subcutaneously 2-3 times daily (fasted). This is a prison of needles. Most users quit after two weeks.
Discovered by Dr. Michael Z. K. in the early 1990s, Fragment 176-191 is the active site of the growth hormone molecule. It isolates the fat-burning mechanism (lipolysis) while theoretically bypassing the negative feedback loops.